Axa S.A. Sorrento Therapeutics, Inc. Transaction History

Axa S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.74 - $1.83 $256,706 - $634,827	346,900 Added 81.18%	774,200 $689,000
Q2 2022 Aug 15, 2022	BUY	$1.24 - $2.33 $529,852 - $995,609	427,300 New	427,300 $859,000
Q1 2022 May 13, 2022	SELL	$2.0 - $4.9 $59,600 - $146,020	-29,800 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$7.41 - $10.99 $220,818 - $327,502	29,800 New	29,800 $227,000
Q2 2020 Aug 14, 2020	SELL	$1.73 - $6.76 $118,678 - $463,736	-68,600 Closed	0 $0
Q4 2019 Feb 18, 2020	SELL	$1.45 - $4.17 $3,480 - $10,008	-2,400 Reduced 3.38%	68,600 $232,000
Q2 2019 Aug 13, 2019	SELL	$2.67 - $4.38 $155,661 - $255,354	-58,300 Reduced 45.09%	71,000 $190,000
Q1 2019 May 14, 2019	SELL	$1.86 - $5.94 $299,088 - $955,152	-160,800 Reduced 55.43%	129,300 $614,000
Q3 2018 Nov 08, 2018	BUY	$4.22 - $7.5 $926,290 - $1.65 Million	219,500 Added 310.91%	290,100 $1.28 Million
Q2 2018 Aug 13, 2018	BUY	$4.75 - $8.0 $335,350 - $564,800	70,600 New	70,600 $508,000

5.47M

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.